Skip to main content

Day: March 7, 2023

Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 7, 2023, 8:30 a.m. ET  Newly rebranded Zevra Therapeutics well positioned to become a commercially focused rare disease company Arimoclomol NDA resubmission on track to be filed as early as Q3 2023 KP1077 Phase 2 Trial on track to deliver preliminary data as early as Q3 2023 and top-line data as early as year-end 2023 AZSTARYS® royalty revenue growing with one or more revenue milestones expected to be achieved in 2023 Strong balance sheet with cash, cash equivalents and investments of $102.9 million which extends the cash runway into 2026 CELEBRATION, Fla., March 07, 2023 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra,” or “the Company,” formerly “KemPharm, Inc.”), a rare disease therapeutics company, today reported its...

Continue reading

Xtant Medical Announces Fourth Quarter and Full Year 2022 Financial Results

BELGRADE, Mont., March 07, 2023 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2022. “Highlighted by strong fourth quarter revenue results and last week’s acquisition of the Coflex® product line, we are executing on our key growth initiatives,” said Sean Browne, President and CEO of Xtant Medical. “We continue to generate robust demand for our biologics products, which grew 14% for the quarter, and improve our operating efficiencies by increasing our production capacity that now has us well-positioned to sustain our momentum in 2023. Additionally, with the addition of the Coflex product line, we significantly...

Continue reading

Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights

– Demonstrated early proof-of-concept for cNeT therapy in heavily pre-treated advanced NSCLC patients – – Exhibited power of translational science platform by correlating anti-tumor activity of cNeT with targeting of clonal neoantigens – – Strong cash position of $173.3 million supports operations into mid-2025 –   LONDON, March 07, 2023 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the fourth quarter and year-ended December 31, 2022, and recent business highlights. “In 2022, we were pleased to deliver early proof-of-concept data supporting the promise of our clonal neoantigen-reactive T cell, or...

Continue reading

First Watch Restaurant Group, Inc. Reports Strong 2022 Financial Results and Provides 2023 Outlook

Total revenues of $730.2 million, up 21.5% and System-wide sales of $914.8 million, up 21.9% Same-restaurant sales growth of 14.5% and Same-restaurant traffic growth of 7.7% Income from operations margin of 2.4% and Restaurant level operating profit margin of 17.9% 43 system-wide restaurants opened across 16 statesBRADENTON, Fla., March 07, 2023 (GLOBE NEWSWIRE) — Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, today reported financial results for the thirteen weeks ended December 25, 2022 (“Q4 2022”) and fiscal year ended December 25, 2022 (“2022”) compared to the thirteen weeks ended December 26, 2021 (“Q4 2021”) and fiscal year ended December 26, 2021 (“2021”) and provided an outlook for the fiscal year ending December 31,...

Continue reading

Freight Technologies, Inc. Reports Strong Revenue Growth: YTD Revenue Reaches $25.9 Million, Up 20.3% from Prior Year; Almost 40% Annual Revenue Growth Projected for 2023

Fr8Tech’s Q4 2022 Performance: Strong Fr8Fleet Results Counterbalance Dip in Shipments from Key Account HOUSTON, March 07, 2023 (GLOBE NEWSWIRE) — Freight Technologies, Inc. (Nasdaq: FRGT) (“Fr8Tech”), a technology company offering its custom-developed Fr8App, an industry-leading freight-matching platform powered by AI and machine-learning that offers a real-time portal for B2B cross-border and domestic shipping within the USMCA region, today reports fourth quarter 2022 revenue for the period ended Dec. 31, 2022. Fr8Tech reported $4.4 million in quarterly revenue for Q4 2022, and YTD 2022 revenue reached an impressive $25.9 million, up 20.6% from the prior year. With eyes set firmly on the future, Fr8Tech’s management announced 2023 revenue guidance of $36 million, representing almost 40% growth from Fr8App’s...

Continue reading

Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational Progress

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL) met the primary endpoint in the pivotal Phase 2 FELIX study and is on track for next data update at a medical conference in mid-2023 with a Biologics License Application (BLA) submission to the US FDA planned by end of the yearObe-cel data presented at ASH demonstrated 35% of relapsed/refractory adult ALL patients in the ALLCAR19 study remain in complete remission at a median follow up of 36 months without the need for additional anti-leukemia therapyPotentially best-in-class profile of obe-cel supported by data observed in non-Hodgkin lymphoma (NHL) patients in the ALLCAR19 study, with continued high levels of clinical activity and an encouraging tolerability profile across DLBCL, MCL, FL and CLLFunds secured...

Continue reading

Iris Energy Announces Monthly Investor Update for February 2023

Figure 1 Childress – data center internal electrical fit outFigure 2 Childress – data center exhaust fan installationFigure 3 Childress – High School chemistry classDaily average operating hashrate chart Daily average operating hashrate chartIncreasing self-mining capacity from 2.0 EH/s to 5.5 EH/s Reported financial results for 2Q FY23 SYDNEY, Australia, March 07, 2023 (GLOBE NEWSWIRE) — Iris Energy Limited (NASDAQ: IREN) (“Iris Energy” or “the Company”), a leading owner and operator of institutional-grade, highly efficient proprietary Bitcoin mining data centers powered by 100% renewable energy, today published a monthly investor update for February 2023, containing its results from operations as well as business updates. Key Highlights1Key metrics2 Feb-23Average operating hashrate (PH/s) 1,730Bitcoin...

Continue reading

SKEL fjárfestingafélag hf.: AGM 9 March 2023 – Candidates to the Board of Directors and Nomination Committee

SKEL fjárfestingafélag hf.’s Annual General Meeting will be held on Thursday, 9 March 2023 at 16:00 in the Ballroom at the Reykjavík Edition, Austurbakki 2, 101 Reykjavík. The deadline for declaring candidacy for the Board of Directors has passed. The following are the candidates for the Board of Directors of SKEL:Birna Ósk Einarsdóttir Guðni Rafn Eiríksson Jón Ásgeir Jóhannesson Nanna Björk Ásgrímsdóttir Sigurður Kristinn EgilssonAccording to the Company’s Articles of Association the Annual General Meeting elects five members for the Board of Directors and therefore the candidates will be elected without ballot at the meeting. Further information on each candidate and the Nomination Committee’s proposal can be found in the attached document and on SKEL’s website: https://skel.is/en/shareholders/shareholder-meetings The...

Continue reading

Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

– Podium presentation on Phase 2 phenylketonuria (PKU) data – – Poster presentations on Phase 1 homocystinuria (HCU) data and HCU preclinical data – CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that it will present a podium presentation and two poster presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting in Salt Lake City, Utah on March 19, 2023.Podium Presentation: Synpheny-1: A Phase 2 Study of the Efficacy and Safety of SYNB1618 and SYNB1934 in Patients with Phenylketonuria Presenting author: Dr. Jerry Vockley, MD, PhD, Director, Center for Rare Disease Therapy, Chief, Medical Genetics at UPMC Children’s Hospital of Pittsburgh, Professor of Pediatrics and Human Genetics...

Continue reading

Form 8.3 – [Devro plc – 06 03 2023] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree DEVRO PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.